Omeros Shares Soar as FDA Clears Rare Disease Drug Yartemlea (1)

(Updates with shares.)

Omeros shares surge as much as 102%, reaching the highest intraday since May 2021, after the biopharmaceutical company received FDA approval for Yartemlea (narsoplimab-wuug) in hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and children ages 2 and older.

• US commercial launch planned for January 2026
• European marketing authorization currently under review, with a decision expected in mid-2026
• Omeros shares were halted for pending news and have since resumed trading

ANALYST COMMENTARY

• HC Wainwright & Co, Brandon Folkes (buy)
  • Says that this approval validates his view of significant value potential for OMER
  • “We view the YARTEMLEA approval, ...